Case Reports
3 May 2022
Vol. 74 No. 1 (2022)
COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
2091
Views
546
Downloads
Authors
Borges et al. have recently reported the first case of a dermatomyositis onset in close association with established coronavirus disease 2019 (COVID-19). Similarly, we report a patient who, on the contrary, had COVID-19 following early established dermatomyositis. We report prospectively the outcome of her disease.
Altmetrics
Downloads
Download data is not yet available.
Citations
Lundberg I, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017; 76: 2271-82. DOI: https://doi.org/10.1002/art.40320
Borges NH, Godoy TM, Kahlo BS. Insorgenza di dermatomiosite in stretta associazione con COVID-19 - un primo caso riportato. Rheumatology (Oxford) 2021.[Epub ahead of print].
Ahmed S, Zimba O, Gasparyan AY. COVID-19 e il corso clinico delle manifestazioni reumatiche. Clin Rheumatol. 2021: 1-9.
Raghavan S, Gonakoti S, Asemota IR, Mba B. Un caso di flare di lupus eritematoso sistemico innescato da una grave malattia da coronavirus 2019. J Clin Rheumatol. 2020; 26: 234-36. DOI: https://doi.org/10.1097/RHU.0000000000001531
Lokineni S, Mortezavi M. Miosite necrotizzante a insorgenza ritardata dopo infezione da COVID-19. Eur J Case Rep Int Med. 2021; 8: 002461.
De Souza JM, Hoff LS, Shinjo SK. Terapie a impulsi di immunoglobulina umana per via endovenosa e/o metilprednisolone come possibile strategia treat-to-target nelle miopatie necrotizzanti immunomediate. Rheumatol Int. 2019; 39: 1201-12. DOI: https://doi.org/10.1007/s00296-019-04254-3
De Souza, Miossi R, Shinjo SK. Miopatia necrotizzante associata ad anticorpo anti-signal recognition particle (anti-SRP). Clin Exp Rheumatol. 2017; 35: 766-71.
How to Cite
COVID-19 as potential aggravating factor for the natural course of new onset-dermatomyositis. (2022). Reumatismo, 74(1). https://doi.org/10.4081/reumatismo.2022.1440
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
